Hazardous Material Survey Report Bronx Windows Phase 1 Nov 2020.pdf

HOLIHAN ASSOCIATES LLC | 5 BULL RUN COURT, BEAUFORT, SC 29907 | PHONE: 571 242-7242

Hazardous Material Survey Report Prepared

27 August 2020

For

James J, Peters Veterans Affairs Medical Center, Bronx New York 10468

Replace Exterior Windows - Phase 1

Contract No. 36C24220C0035

Project No. 526-18-103 Purchase Order 526C00135

Submittal Date: November 2020

Final Design Submission

Pre-Renovation Hazardous Materials Survey Report

James J. Peters VA Medical Center Window Replacement Project

Phase 1

Bronx, New York

CHA Project Number: 060257

Prepared for:

Beaufort Engineering Services, Inc

2717 Bull Street Beaufort, South Carolina, 29902

Prepared by:

III Winners Circle

Albany, New York 12205 Phone: (518) 453-4500

August 27, 2020

V:\Projects\ANY\K5\060257.000\Reports\Pre-Renovation Hazmat Survey Report\Draft\Pre-Renovation Hazardous Materials Survey Report (revised 8-27-20).doc

Bronx VA Hospital Pre-Renovation Hazardous Material Survey Report CHA Project No. 060257 Page i

QUALIFICATIONS AND CERTIFICATION STATEMENT

This Limited Pre-Renovation Hazardous Materials Survey Report was compiled by a qualified environmental scientist who is also an EPA-certified asbestos inspector employed by CHA.

This report has been prepared expressly for the use of Beaufort Engineering Services, Inc. and the

James J. Peters VA Medical Center. No other parties are entitled to rely upon this report unless our express written consent is first obtained. All conclusions drawn were based on CHA’s review of available historical data, field inspection and analytical results from sampling performed during the course of this project. Recommendations are submitted based on CHA's knowledge, experience, and professional judgment.

Inspection and Report Completed By:

Scott F. Rosecrans, CHMM

Environmental Scientist IV

Report Reviewed By:

Seth H. Fowler, CHMM

Principal Scientist

Bronx VA Hospital Pre-Renovation Hazardous Material Survey Report CHA Project No. 060257 Page ii

TABLE OF CONTENTS

1.0 INTRODUCTION

2.0 SCOPE OF WORK

2.1 Asbestos-Containing Materials Survey

2.2 PCB in Caulk Survey

2.3 Limitations

3.0 HAZARDOUS MATERIALS SURVEY

3.1 Record Review

3.2 Asbestos-Containing Material Survey

3.3 PCB in Caulk Inspection

4.0 RESULTS

5.0 CONCLUSIONS AND RECOMMENDATIONS

LIST OF FIGURES

Figure 1-9 Building Floor Plans – Limits of Inspection

LIST OF APPENDICES

Appendix A Asbestos Bulk Sample Summary Table Appendix B PCB Bulk Sample Summary Table Appendix C Asbestos Sample Analytical Report Appendix D PCB Sample Analytical Report Appendix E Personnel and Laboratory Licenses

1.0 INTRODUCTION

CHA was retained by the Beaufort Engineering Services, Inc. (BES) to complete a limited Pre-

Renovation Hazardous Materials Survey of the James J. Peters VA Medical Center as part of the

Phase I Window Replacement Project (VA Project No. 526-18-103) currently being designed. The

James J. Peters VA Medical Center is located in the Bronx, New York.

CHA was the environmental consultant on the Phase II window replacement project that was designed by BES, Inc. in 2014. During the Phase II project, a full survey of all impacted areas was undertaken with that survey being limited to the window systems and surrounding surfaces. The

Phase II survey focused on suspect asbestos-containing and suspect PCB-containing window sealants, but also included limited interior finishes that were suspect asbestos-containing materials such as ceiling tiles, sheetrock walls, ceramic wall tiles & grout, and spray-on fireproofing.

This survey report consists of six sections, including this Introduction. Section 2.0 presents the

Scope of Work, which outlines the parameters by which this project was performed and the limitations that were encountered. Section 3.0 – Hazardous Materials Survey, details the building inspection relative to asbestos-containing materials (ACM) and polychlorinated biphenyls (PCBs) associated with the window sealants. Section 4.0 presents a brief overview of the inspection results while Section 5.0 presents CHA’s conclusions and recommendations regarding the status of the areas that were inspected.

2.0 SCOPE OF WORK

The Phase I Window Replacement Project includes only the eastern elevations of the main hospital building. The elevations and windows that are currently in scope are shown on Figures 1 – 9.

CHA’s inspection included only window systems on these elevations. Based on the procedures and work impacts determined by the Phase II design project, the Phase I survey was limited to the windows systems and sealants themselves, as surrounding interior finishes will not be impacted by the work of the Phase I project. All work has been completed in accordance with applicable federal, state, and local regulations.

2.1 ASBESTOS-CONTAINING MATERIALS SURVEY

CHA performed a limited pre-renovation asbestos-containing material (ACM) survey of the window systems on the east side of the main building. An EPA-certified asbestos building inspector was responsible for the identification and assessment of the condition, location, and quantity of suspect

ACMs associated with the window replacement project. The inspector collected bulk samples of identified suspect ACM following the protocols referenced in 40 CFR Part 763.86 Subpart E

(AHERA). All bulk samples were analyzed at an accredited laboratory certified by the National

Voluntary Laboratory Accreditation Program (NVLAP) for the analysis of asbestos bulk samples.

2.2 PCB IN CAULK SURVEY

The window systems were visually inspected for the presence of caulks and sealants as part of the asbestos survey activities. All window caulk/sealants that were identified as suspect for asbestos were also sampled and transmitted to Chemtech located in Mountainside, N.J. under chain of custody protocol for analysis for PCBs via EPA Method 8082. Chemtech is an Environmental

Laboratory Approval Program (ELAP) and National Environmental Laboratory Accreditation

Program (NELAP) approved laboratory for PCB analysis.

2.3 LIMITATIONS

The figures attached to this report are to scale and were drafted from AutoCAD base plans provided by the BES, Inc. prior to the survey fieldwork.

Interior inspections were limited to accessible spaces along the east side of the building. Since the hospital is active and occupied, many areas were not readily accessible due to hospital activities, patient care, or secure conditions. In particular, due to in-patient occupancy on the 7th and 8th floors, no access was attained in these floors. Random locations on each floor were accessed to allow up close visual inspection of the window systems for suspect materials as well as bulk sample collection. The locations that were accessed are indicated on Figures 1-9. Due to the known consistency of the window systems throughout the building as confirmed by the architectural team and the previous Phase II window replacement project, the number of window locations accessed is considered sufficient for this inspection.

It should be noted that additional suspect ACMs may exist in the areas inspected as well as other areas of the main building but are not anticipated to be impacted by the window replacement project and therefore were not evaluated and are not discussed in this report.

3.0 HAZARDOUS MATERIALS SURVEY

CHA’s background research and field observations during the site inspection with regard to suspect

ACMs associated with the subject area at the James J. Peters VA Medical Center in the Bronx, N.Y.

are discussed below.

3.1 RECORD REVIEW

A Pre-Renovation Hazardous Materials Survey Report has completed by CHA, dated August 14, 2014 as part of the Phase II Window Replacement Project. That report was focused on all windows on the west facing sides of the building and was reviewed and referenced in preparation for this survey effort.

The 2014 report indicates that asbestos was not detected in the sheetrock, joint compound, paper/foil on fiberglass insulation, rigid sprayed-on insulation, soft sprayed-on insulation, 2’ x 2’ ceiling tiles, 2’x 4’ ceiling tiles, ceramic wall tiles, and associated mastics and grouts and numerous window sealants. It also indicates that the only asbestos-containing window sealant present was a window glazing present on the interior of the split window pane system. All paint chip samples that were analyzed for lead were found to have no detectable levels of lead. It was found that no paint was present on the window system as they appear to have an anodized finish. Samples of window sealants tested for PCBs were found to have no PCBs detected.

3.2 ASBESTOS-CONTAINING MATERIAL SURVEY

As discussed in Section 2.1 above, the survey focused on the window systems themselves and the associated sealants. Suspect asbestos-containing materials observed included black window glazing compound (exterior and interior of split window system), black exterior frame caulk, and white caulk at building panel (aluminum) seams.

The bulk samples collected were transmitted under chain of custody to AmeriSci New York, an

ELAP accredited laboratory for asbestos analysis. All of the asbestos samples collected are detailed on Table A-1, included in Appendix A. Samples that were confirmed to be greater than 1.0% asbestos are considered asbestos-containing materials and are shown in bold.

3.3 PCB IN CAULK INSPECTION

The inspection for PCB-containing caulk included the collection of separate samples of all of the caulk/glazing that was identified as part of the asbestos inspection for analysis for PCBs. The bulk samples were transmitted under chain of custody to Chemtech, where they were analyzed for PCB content via EPA Method 8082. A bulk sample summary for the PCB caulk/sealant analysis is included as Table B-1 in Appendix B.

4.0 RESULTS

CHA identified and sampled a total of seven suspect asbestos-containing materials during the limited pre-renovation asbestos survey. Two of those materials, the black window glazing compounds both present on the interior of the split window pane system were found to be positive for asbestos. All other samples had no asbestos detected. Refer to Table A-1 for a summary of all bulk samples, the location from which it was collected, and the analytical result for each sample.

All caulk samples that were analyzed for PCBs were found to have no PCBs detected.

5.0 CONCLUSIONS AND RECOMMENDATIONS

The conclusions and recommendations presented below are based on information gathered in accordance with the Scope of Work defined in this section of the report. Based upon CHA’s review of the analytical results and observations made during the limited inspection, the following conclusions and recommendations have been developed.

The interior window glazing compounds that are sealed in the interior portion of the movable section (sash) of the window system (interior of split window pane system) are positive for asbestos. The removal of this movable section of the window system must be handled as an asbestos abatement project by properly trained asbestos abatement workers.

If additional suspect materials are discovered during the project, those materials should be assumed to be asbestos-containing and treated as such until they have been sampled and analyzed for asbestos.

The window sealants that were analyzed for PCBs were all found to contain no PCBs. There is no special management required for this window replacement project pertaining to PCB sealants.

No paint was observed associated with the window systems, as they appear to be an anodized finish.

This inspection report shall not solely serve as an asbestos abatement design document for obtaining bids from abatement contractors. It is recommended that specific abatement design documents be prepared in order to specify procedures and protocols that must be observed in order to ensure that abatement activities are completed in a manner consistent with local, state and federal regulations and requirements.

Per New York State Code Rule 56-5.1(g) Transmittal of Building/Structure Asbestos Survey

Information, the completed asbestos survey report shall be immediately transmitted by the owner or their agent to the local government entity charged with issuing a permit for such demolition, renovation, remodeling, or repair work under applicable State or local laws.

New York State considers any removal of load bearing structural supports as a demolition activity. Since the current project calls for the renovation of this building, it is also the building owner’s responsibility to transmit this report to the appropriate Asbestos Control

Bureau district office. The local district office contact information is provided below.

Asbestos Control Bureau – New York City District

One Hudson Square

75 Varick Street, 7th Floor

New York, NY 10013

(212) 775-3532

FIGURES

Drawing Copyright © 2020

III Winners Circle, PO Box 5269

518.453.4500 Albany, NY 12205-0269

www.chacompanies.com

STORAGE

AREA

SPECIAL CHEMISTRY

CHEMISTRY

ACCESSIONING

URINALYSIS

HEMATOLOGY

Drawing Copyright © 2020

III Winners Circle, PO Box 5269

518.453.4500

518.453.4500

518.453.4500

518.453.4500

518.453.4500

518.453.4500

518.453.4500

518.453.4500

APPENDIX A

Asbestos Bulk Sample Summary Table

TABLE A-1

ASBESTOS BULK SAMPLE SUMMARY

Bronx VA Hospital

Window Replacment Project - Phase I

Sample Number Suspect Material Description Sample Location Asbestos

Content (%)

080620-SR-01A Black Interior Window Glazing Compound First Floor, North Corridor NAD

080620-SR-01B Black Interior Window Glazing Compound First Floor, North Corridor NAD

080620-SR-02A White Exterior Aluminum to Aluminum Panel Caulk First Floor, Adjacent to Main Entrance NAD

080620-SR-02B White Exterior Aluminum to Aluminum Panel Caulk First Floor, Adjacent to Main Entrance NAD

080620-SR-03A Exterior Window Frame Caulk - Black Room 2C-14 NAD

080620-SR-03B Exterior Window Frame Caulk - Black Third Floor, North Hallway Front NAD

080620-SR-03C Exterior Window Frame Caulk - Black Room 4B-17 NAD

080620-SR-03D Exterior Window Frame Caulk - Black Room 5A-14 NAD

080620-SR-03E Exterior Window Frame Caulk - Black Sixth Floor, South, Unit 6C NAD

080620-SR-04A

Window Glazing Compound - interior of pane (sash) -outer (similar to 06 sample group) Room 2C-14 Chrysotile 6.7%

080620-SR-04B

Window Glazing Compound - interior of pane (sash) -outer (similar to 06 sample group) Third Floor, North Hallway Front NA Stop 1st

080620-SR-04C

Window Glazing Compound - interior of pane (sash) -outer (similar to 06 sample group) Room 4B-17 NA Stop 1st

080620-SR-04D

Window Glazing Compound - interior of pane (sash) -outer (similar to 06 sample group) Room 5A-14 NA Stop 1st

080620-SR-04E

Window Glazing Compound - interior of pane (sash) -outer (similar to 06 sample group) Sixth Floor, South, Unit 6C NA Stop 1st

080620-SR-05A Exterior Window Glazing Compound - Black Room 2C-14 NAD

080620-SR-05B Exterior Window Glazing Compound - Black Third Floor, North Hallway Front NAD

080620-SR-05C Exterior Window Glazing Compound - Black Room 4B-17 NAD

080620-SR-05D Exterior Window Glazing Compound - Black Room 5A-14 NAD

080620-SR-05E Exterior Window Glazing Compound - Black Sixth Floor, South, Unit 6C NAD

080620-SR-06A

Window Glazing Compound - interior of pane (sash) -inner (similar to 04 sample group) Room 2C-14 Chrysotile 5.8%

080620-SR-06B

Window Glazing Compound - interior of pane (sash) -inner - (similar to 04 sample group) Third Floor, North Hallway Front NA Stop 1st

080620-SR-06C

Window Glazing Compound - interior of pane (sash) -inner - (similar to 04 sample group) Room 4B-17 NA Stop 1st

080620-SR-06D

Window Glazing Compound - interior of pane (sash) -inner - (similar to 04 sample group) Room 5A-14 NA Stop 1st

080620-SR-06E

Window Glazing Compound - interior of pane (sash) -inner - (similar to 04 sample group) Sixth Floor, South, Unit 6C NA Stop 1st

080620-SR-07A Interior Window Glazing Compound - exterior to sash Room 2C-14 NAD

080620-SR-07B Interior Window Glazing Compound - exterior to sash Third Floor, North Hallway Front NAD

080620-SR-07C Interior Window Glazing Compound - exterior to sash Room 4B-17 NAD

080620-SR-07D Interior Window Glazing Compound - exterior to sash Room 5A-14 NAD

080620-SR-07E Interior Window Glazing Compound - exterior to sash Sixth Floor, South, Unit 6C NAD

NAD - No Asbestos Detected

NA Stop 1st - Sample not analyzed as previous sample in homogenous group was found positive

BOLD - Greater than 1.0% Asbestos - Considered an Asbestos-Containing Material

CHA Consulting, Inc. Asbestos-Containing Materials Survey

APPENDIX B

PCB Bulk Sample Summary Table

TABLE B-1

PCB SAMPLE SUMMARY

Bronx VA Hospital Window Replacement Project - Phase I

Sample Number Suspect Material Description Sample Location

PCB

Concentration (mg/KG)

PCB-080620-SR-01 Black Interior Window Glazing Compound First Floor, North Corridor ND

PCB-080620-SR-02 White Aluminum Panel to Panel Caulk First Floor, Adjacent to Main Entrance ND

PCB-080620-SR-03 Black Exterior Window Frame Caulk Room 2C-14 ND

PCB-080620-SR-04 Black Exterior Window Frame Caulk Room 4B-27 ND

PCB-080620-SR-05 Black Exterior Window Frame Caulk Sixth Floor, South (Unit 6C) ND

PCB-080620-SR-06 Window Glazing Compound - interior of pane (sash) - outer Third Floor, North Hallway ND

PCB-080620-SR-07 Window Glazing Compound - interior of pane (sash) - outer Room 4B-27 ND

PCB-080620-SR-08 Window Glazing Compound - interior of pane (sash) - outer Room 5A-14 ND

PCB-080620-SR-09 Exterior Window Glazing Compound - Black Room 2C-14 ND

PCB-080620-SR-10 Exterior Window Glazing Compound - Black Room 4B-27 ND

PCB-080620-SR-11 Exterior Window Glazing Compound - Black Sixth Floor, South (Unit 6C) ND

PCB-080620-SR-12 Window Glazing Compound - interior of pane (sash) - inner Third Floor, North Hallway ND

PCB-080620-SR-13 Window Glazing Compound - interior of pane (sash) - inner Room 4B-27 ND

PCB-080620-SR-14 Window Glazing Compound - interior of pane (sash) - inner Room 5A-14 ND

PCB-080620-SR-15 Interior Window Glazing Compound - exterior to sash Room 2C-14 ND

PCB-080620-SR-16 Interior Window Glazing Compound - exterior to sash Room 5A-14 ND

PCB-080620-SR-17 Interior Window Glazing Compound - exterior to sash Sixth Floor, South (Unit 6C) ND Notes:

ND = Not Detected

CHA Consulting, Inc. PCB Survey

APPENDIX C

Asbestos Sample Analytical Reports

APPENDIX D

PCB Sample Analytical Reports

DATA PACKAGE

GC SEMI-VOLATILES

PROJECT NAME : JAMES J. PETERS VA MEDICAL CENTER

CHA COMPANIES, INC.

III Winners Circle

P.O. Box 5269

Albany, NY - 12205-0269

Phone No: 518-453-4500

ORDER ID :

ATTENTION :

L3650

Seth Fowler

Table Of Contents for L3650

1 of 47L3650 http://www.chemtech.net

Table Of Contents for L3650

1) Signature Page 3

2) Case Narrative 4

2.1) PCB- Case Narrative 4

3) Qualifier Page 7

4) QA Checklist 8

5) PCB Data 9

6) Shipping Document 43

6.1) CHAIN OF CUSTODY 44

6.2) Air Bill 46

6.3) Lab Certificate 47

2 of 47L3650

Cover Page

Client Sample NumberLab Sample Number

Client :

Project ID :

Order ID : L3650

James J. Peters VA Medical Center

CHA Companies, Inc.

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

L3650-01 PCB-080620-SR-01

L3650-02 PCB-080620-SR-02

L3650-03 PCB-080620-SR-03

L3650-04 PCB-080620-SR-04

L3650-05 PCB-080620-SR-05

L3650-06 PCB-080620-SR-06

L3650-07 PCB-080620-SR-07

L3650-08 PCB-080620-SR-08

L3650-09 PCB-080620-SR-09

L3650-10 PCB-080620-SR-10

L3650-11 PCB-080620-SR-11

L3650-12 PCB-080620-SR-12

L3650-13 PCB-080620-SR-13

L3650-14 PCB-080620-SR-14

L3650-15 PCB-080620-SR-15

L3650-16 PCB-080620-SR-16

L3650-17 PCB-080620-SR-17

I certify that the data package is in compliance with the terms and conditions of the contract,both technically and for completeness, for other than the conditions detailed above. Release of the data contained in this hard copy data package has been authorized by the laboratory manager or his designee, as verified by the following signature.

Signature :

NJDEP CERTIFICATION NO - 20012NYDOH CERTIFICATION NO - 11376

Date: 8/24/2020

3 of 47L3650 http://www.chemtech.net nimisha Approved nimisha Nimisha Pandya

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

CASE NARRATIVE

CHA Companies, Inc.

Project Name: James J. Peters VA Medical Center Project # N/A Chemtech Project # L3650 Test Name: PCB

A. Number of Samples and Date of Receipt:

17 Solid samples were received on 08/11/2020.

B. Parameters According to the Chain of Custody document, the following analyses were requested:

PCB. This data package contains results for PCB.

C. Analytical Techniques:

The analyses were performed on instrument GCECD_O. The front column is ZB-MR1 which is 30 meters, 0.32 mm ID, 0.5 um df, Catalogue # 7HM-G016-17. The rear column is ZB-MR2 which is 30 meters, 0.32 mm ID, 0.25 µm; Catalogue # 7HM-G017-11.The analysis of PCBs was based on method 8082A and extraction was done based on method 3541.

D. QA/ QC Samples:

The Holding Times were met for all analysis.

The Surrogate recoveries met the acceptable criteria except for PCB-080620-SR-01 [Decachlorobiphenyl(1) - 128%, Decachlorobiphenyl(2) - 234%], PCB-080620-SR-01RE [Decachlorobiphenyl(1) - 145%, Decachlorobiphenyl(2) - 225%], PCB-080620-SR-02 [Decachlorobiphenyl(1) - 142%, Decachlorobiphenyl(2) - 172%], PCB-080620-SR-02RE [Decachlorobiphenyl(1) - 155%, Decachlorobiphenyl(2) - 156%], PCB-080620-SR-03 [Decachlorobiphenyl(1) - 128%, Decachlorobiphenyl(2) - 146%], PCB-080620-SR-03RE [Decachlorobiphenyl(1) - 135%, Decachlorobiphenyl(2) - 128%], PCB-080620-SR-04 [Decachlorobiphenyl(1) - 128%, Decachlorobiphenyl(2) - 150%], PCB-080620-SR-04RE [Decachlorobiphenyl(1) - 135%, Decachlorobiphenyl(2) - 173%], PCB-080620-SR-05 [Decachlorobiphenyl(1) - 132%, Decachlorobiphenyl(2) - 151%], PCB-080620-SR-05RE [Decachlorobiphenyl(1) - 134%, Decachlorobiphenyl(2) - 143%], PCB-080620-SR-06 [Decachlorobiphenyl(1) - 153%, Tetrachloro-m-xylene(2) - 209%], PCB-080620-SR-07 [Decachlorobiphenyl(1) - 226%, Decachlorobiphenyl(2) - 156%, Tetrachloro-m-xylene(1) - 194%, Tetrachloro-m-xylene(2) - 228%], PCB-080620-SR-07RE [Decachlorobiphenyl(1) - 171%, Tetrachloro-m-xylene(2) - 330%], PCB-080620-SR-08 [Decachlorobiphenyl(1) - 130%], PCB-080620-SR-09 [Decachlorobiphenyl(1) - 142%, Decachlorobiphenyl(2) - 149%], PCB-080620-SR-09RE [Decachlorobiphenyl(1) - 153%, Decachlorobiphenyl(2) - 161%], PCB-080620-SR-10 [Decachlorobiphenyl(1) - 130%, Decachlorobiphenyl(2) - 152%], 2.1

4 of 47L3650

PCB-080620-SR-10RE [Decachlorobiphenyl(1) - 139%, Decachlorobiphenyl(2) - 144%], PCB-080620-SR-11 [Decachlorobiphenyl(1) - 128%, Decachlorobiphenyl(2) - 153%], PCB-080620-SR-11RE [Decachlorobiphenyl(1) - 142%, Decachlorobiphenyl(2) - 137%], PCB-080620-SR-12 [Decachlorobiphenyl(1) - 132%, Decachlorobiphenyl(2) - 127%], PCB-080620-SR-13 [Decachlorobiphenyl(2) - 145%, Tetrachloro-m-xylene(1) - 236%], PCB-080620-SR-14 [Decachlorobiphenyl(1) - 239%, Decachlorobiphenyl(2) - 152%, Tetrachloro-m-xylene(1) - 194%, Tetrachloro-m-xylene(2) - 343%], PCB-080620-SR-14RE [Decachlorobiphenyl(1) - 159%, Decachlorobiphenyl(2) - 131%, Tetrachloro-m-xylene(1) - 280%, Tetrachloro-m-xylene(2) - 422%], PCB-080620-SR-15 [Decachlorobiphenyl(1) - 153%, Decachlorobiphenyl(2) - 175%], PCB-080620-SR-15RE [Decachlorobiphenyl(1) - 162%, Decachlorobiphenyl(2) - 179%], PCB-080620-SR-16 [Decachlorobiphenyl(1) - 132%, Decachlorobiphenyl(2) - 313%], PCB-080620-SR-16RE [Decachlorobiphenyl(1) - 145%, Decachlorobiphenyl(2) - 310%], PCB-080620-SR-17 [Decachlorobiphenyl(1) - 163%, Decachlorobiphenyl(2) - 247%, Tetrachloro-m-xylene(1) - 179%, Tetrachloro-m-xylene(2) - 167%], PCB-080620-SR-17RE [Decachlorobiphenyl(1) - 172%, Decachlorobiphenyl(2) - 258% and Tetrachloro-m-xylene(1) - 168% Re-analysis provided for surrogate failure confirmation.

AS per SOW method one surrogate allowed to fail to meet the criteria per column. No further corrective action was taken.

The Retention Times were acceptable for all samples.

The Blank Spike met requirements for all samples .

The Blank analysis did not indicate the presence of lab contamination.

The Initial Calibration met the requirements .

The Continuous Calibration met the requirements .

Samples PCB-080620-SR-01, PCB-080620-SR-02, PCB-080620-SR-03, PCB-080620-

SR-04, PCB-080620-SR-05, PCB-080620-SR-06, PCB-080620-SR-07, PCB-080620-

SR-08, PCB-080620-SR-09, PCB-080620-SR-10, PCB-080620-SR-11, PCB-080620-

SR-12, PCB-080620-SR-13, PCB-080620-SR-14, PCB-080620-SR-15, PCB-080620-

SR-16 and PCB-080620-SR-17 were diluted due to bad matrices,All these samples were Glazing and Caulking material,.also samples were having strong odour and dark yellowish brown color,Therefore as precautionary measure we had analyzed some samples with straight 10x dilution and some with straight 5x dilution. Chromatogram for all these samples looks very bad,Due to Sample nature it was not plausible for us to run these samples undiluted.

E. Additional Comments:

The temperature of the samples at the time of receipt was 19.8.

As per special requirement for this project form-1 are reported in mg/kg.

F. Manual Integration Comments:

Please refer to the Manual integration Report included with the Run Logs for information on the manual integrations performed.

2.1

5 of 47L3650

I certify that the data package is in compliance with the terms and conditions of the contract, both technically and for completeness, for other than the conditions detailed above. The laboratory manager or his designee, as verified by the following signature has authorized release of the data contained in this hard copy data package.

Signature__________________________

2.1

6 of 47L3650 nimisha Approved

QA Control # A3040960

284 Sheffield Street, Mountainside NJ 07092 Tel. 908-789-8900 Fax: 908-789-8922

DATA REPORTING QUALIFIERS- ORGANIC

For reporting results, the following “ Results Qualifiers” are used:

Value If the result is a value greater than or equal to the detection limit, report the value

U Indicates the compound was analyzed for but was not detected. Report the minimum detection limit for the sample with the U, i.e. “10 U”. This is not necessarily the instrument detection limit attainable for this particular sample based on any concentration or dilution that may have been required.

ND Indicates the analyte was analyzed for, but not detected

J Indicates an estimated value. This flag is used:

(1) When estimating a concentration for a tentatively identified compound (library search hits, where a 1:1 response is assumed.)

(2) When the mass spectral data indicated the identification, however the result was less than the specified detection limit greater than zero. If the detection limit was 10ug/L and a concentration of 3 ug/L was calculated report as 3 J. This is flag is used when similar situation arise on any organic parameter i.e. Pest, PCB and others.

B Indicates the analyte was found in the blank as well as the sample report as “12 B”.

E Indicates the analyte ‘s concentration exceeds the calibrated range of the instrument for that specific analysis.

D This flag identifies all compounds identified in an analysis at a secondary dilution factor.

P This flag is used for Pesticide/PCB target analyte when there is >25% difference for detected concentrations between the two GC columns. The lower of the two values is reported on Form 1 and flagged with a “P”.

N This flag indicates presumptive evidence of a compound. This is only used for tentatively identified compounds (TICs), where the identification is based on a mass spectral library search. It applies to all TIC results. For generic characterization of a TIC, such as chlorinated hydrocarbon, the flag is not used.

A This flag indicates that a Tentatively Identified Compound is a suspected aldol-condensation product.

Q Indicates the LCS did not meet the control limits requirements

7 of 47L3650

APPENDIX A

QA REVIEW GENERAL DOCUMENTATION

Project #:

Completed

For thorough review, the report must have the following:

GENERAL:

Are all original paperwork present (chain of custody, record of communication,airbill, sample management lab chronicle, login page)

Check chain-of-custody for proper relinquish/return of samples

Is the chain of custody signed and complete

Check internal chain-of-custody for proper relinquish/return of samples /sample extracts

Collect information for each project id from server. Were all requirements followed

COVER PAGE:

Do numbers of samples correspond to the number of samples in the Chain of Custody on login page

Do lab numbers and client Ids on cover page agree with the Chain of Custody

CHAIN OF CUSTODY:

Do requested analyses on Chain of Custody agree with form I results

Do requested analyses on Chain of Custody agree with the log-in page

Were the correct method log-in for analysis according to the Analytical Request and Chain of Castody

Were the samples received within hold time

Were any problems found with the samples at arrival recorded in the Sample Management Laboratory

Chronicle

ANALYTICAL:

Was method requirement followed?

Was client requirement followed?

Does the case narrative summarize all QC failure?

All runlogs and manual integration are reviewed for requirements

1st Level QA Review Signature: Date:

2nd Level QA Review Signature: Date:

ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü

APARNA SONI

L3650

08/24/2020

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922 ü

All manual calculations and /or hand notations verified ü

8 of 47L3650 http://www.chemtech.net nimisha Approved

SA

AM

DA

MPL

ATA

LE

A

A

B

C

9 of 47L3650

Report of Analysis

Client:

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-01

L3650-01

SW8082A

08/06/20

08/11/20

GLAZING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/11/20 18:12 PB130902

CAS Number Parameter Conc. Qualifier

5.8 10000Units:

PCB

g

PO070477.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.44U0.10Aroclor-101612674-11-2 0.10 mg/Kg0.44U0.17Aroclor-122111104-28-2 0.17 mg/Kg0.44U0.12Aroclor-123211141-16-5 0.12 mg/Kg0.44U0.15Aroclor-124253469-21-9 0.15 mg/Kg0.44U0.16Aroclor-124812672-29-6 0.16 mg/Kg0.44U0.17Aroclor-125411097-69-1 0.17 mg/Kg0.44U0.11Aroclor-126237324-23-5 0.11 mg/Kg0.44U0.100Aroclor-126811100-14-4 0.100 mg/Kg0.44U0.074Aroclor-126011096-82-5 0.074

SURROGATES

SPK: 20116%23.1Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20234%*46.8Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

10 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-01RE

L3650-01RE

SW8082A

08/06/20

08/11/20

GLAZING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/12/20 10:13 PB130902

CAS Number Parameter Conc. Qualifier

5.8 10000Units:

PCB

g

PO070499.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.44U0.10Aroclor-101612674-11-2 0.10 mg/Kg0.44U0.17Aroclor-122111104-28-2 0.17 mg/Kg0.44U0.12Aroclor-123211141-16-5 0.12 mg/Kg0.44U0.15Aroclor-124253469-21-9 0.15 mg/Kg0.44U0.16Aroclor-124812672-29-6 0.16 mg/Kg0.44U0.17Aroclor-125411097-69-1 0.17 mg/Kg0.44U0.11Aroclor-126237324-23-5 0.11 mg/Kg0.44U0.100Aroclor-126811100-14-4 0.100 mg/Kg0.44U0.074Aroclor-126011096-82-5 0.074

SURROGATES

SPK: 20139%27.7Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20225%*45.0Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

11 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-02

L3650-02

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/11/20 18:29 PB130902

CAS Number Parameter Conc. Qualifier

12.8 10000Units:

PCB

g

PO070478.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.20U0.048Aroclor-101612674-11-2 0.048 mg/Kg0.20U0.078Aroclor-122111104-28-2 0.078 mg/Kg0.20U0.053Aroclor-123211141-16-5 0.053 mg/Kg0.20U0.068Aroclor-124253469-21-9 0.068 mg/Kg0.20U0.071Aroclor-124812672-29-6 0.071 mg/Kg0.20U0.077Aroclor-125411097-69-1 0.077 mg/Kg0.20U0.048Aroclor-126237324-23-5 0.048 mg/Kg0.20U0.045Aroclor-126811100-14-4 0.045 mg/Kg0.20U0.033Aroclor-126011096-82-5 0.033

SURROGATES

SPK: 20124%24.8Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20172%*34.4Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

12 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-02RE

L3650-02RE

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/12/20 10:30 PB130902

CAS Number Parameter Conc. Qualifier

12.8 10000Units:

PCB

g

PO070500.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.20U0.048Aroclor-101612674-11-2 0.048 mg/Kg0.20U0.078Aroclor-122111104-28-2 0.078 mg/Kg0.20U0.053Aroclor-123211141-16-5 0.053 mg/Kg0.20U0.068Aroclor-124253469-21-9 0.068 mg/Kg0.20U0.071Aroclor-124812672-29-6 0.071 mg/Kg0.20U0.077Aroclor-125411097-69-1 0.077 mg/Kg0.20U0.048Aroclor-126237324-23-5 0.048 mg/Kg0.20U0.045Aroclor-126811100-14-4 0.045 mg/Kg0.20U0.033Aroclor-126011096-82-5 0.033

SURROGATES

SPK: 20125%25.1Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20156%*31.3Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

13 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-03

L3650-03

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/11/20 18:46 PB130902

CAS Number Parameter Conc. Qualifier

3.75 10000Units:

PCB

g

PO070479.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.68U0.16Aroclor-101612674-11-2 0.16 mg/Kg0.68U0.27Aroclor-122111104-28-2 0.27 mg/Kg0.68U0.18Aroclor-123211141-16-5 0.18 mg/Kg0.68U0.23Aroclor-124253469-21-9 0.23 mg/Kg0.68U0.24Aroclor-124812672-29-6 0.24 mg/Kg0.68U0.26Aroclor-125411097-69-1 0.26 mg/Kg0.68U0.16Aroclor-126237324-23-5 0.16 mg/Kg0.68U0.15Aroclor-126811100-14-4 0.15 mg/Kg0.68U0.11Aroclor-126011096-82-5 0.11

SURROGATES

SPK: 20128%25.6Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20146%*29.1Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

14 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-03RE

L3650-03RE

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/12/20 10:47 PB130902

CAS Number Parameter Conc. Qualifier

3.75 10000Units:

PCB

g

PO070501.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.68U0.16Aroclor-101612674-11-2 0.16 mg/Kg0.68U0.27Aroclor-122111104-28-2 0.27 mg/Kg0.68U0.18Aroclor-123211141-16-5 0.18 mg/Kg0.68U0.23Aroclor-124253469-21-9 0.23 mg/Kg0.68U0.24Aroclor-124812672-29-6 0.24 mg/Kg0.68U0.26Aroclor-125411097-69-1 0.26 mg/Kg0.68U0.16Aroclor-126237324-23-5 0.16 mg/Kg0.68U0.15Aroclor-126811100-14-4 0.15 mg/Kg0.68U0.11Aroclor-126011096-82-5 0.11

SURROGATES

SPK: 20124%24.7Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20135%*26.9Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

15 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-04

L3650-04

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/11/20 19:04 PB130902

CAS Number Parameter Conc. Qualifier

13.18 10000Units:

PCB

g

PO070480.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.19U0.046Aroclor-101612674-11-2 0.046 mg/Kg0.19U0.076Aroclor-122111104-28-2 0.076 mg/Kg0.19U0.052Aroclor-123211141-16-5 0.052 mg/Kg0.19U0.066Aroclor-124253469-21-9 0.066 mg/Kg0.19U0.069Aroclor-124812672-29-6 0.069 mg/Kg0.19U0.075Aroclor-125411097-69-1 0.075 mg/Kg0.19U0.047Aroclor-126237324-23-5 0.047 mg/Kg0.19U0.044Aroclor-126811100-14-4 0.044 mg/Kg0.19U0.032Aroclor-126011096-82-5 0.032

SURROGATES

SPK: 20132%26.3Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20150%*29.9Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

16 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-04RE

L3650-04RE

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/12/20 11:04 PB130902

CAS Number Parameter Conc. Qualifier

13.18 10000Units:

PCB

g

PO070502.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.19U0.046Aroclor-101612674-11-2 0.046 mg/Kg0.19U0.076Aroclor-122111104-28-2 0.076 mg/Kg0.19U0.052Aroclor-123211141-16-5 0.052 mg/Kg0.19U0.066Aroclor-124253469-21-9 0.066 mg/Kg0.19U0.069Aroclor-124812672-29-6 0.069 mg/Kg0.19U0.075Aroclor-125411097-69-1 0.075 mg/Kg0.19U0.047Aroclor-126237324-23-5 0.047 mg/Kg0.19U0.044Aroclor-126811100-14-4 0.044 mg/Kg0.19U0.032Aroclor-126011096-82-5 0.032

SURROGATES

SPK: 20124%24.9Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20173%*34.6Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

17 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-05

L3650-05

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/11/20 19:21 PB130902

CAS Number Parameter Conc. Qualifier

7.33 10000Units:

PCB

g

PO070481.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.35U0.083Aroclor-101612674-11-2 0.083 mg/Kg0.35U0.14Aroclor-122111104-28-2 0.14 mg/Kg0.35U0.093Aroclor-123211141-16-5 0.093 mg/Kg0.35U0.12Aroclor-124253469-21-9 0.12 mg/Kg0.35U0.12Aroclor-124812672-29-6 0.12 mg/Kg0.35U0.13Aroclor-125411097-69-1 0.13 mg/Kg0.35U0.084Aroclor-126237324-23-5 0.084 mg/Kg0.35U0.079Aroclor-126811100-14-4 0.079 mg/Kg0.35U0.058Aroclor-126011096-82-5 0.058

SURROGATES

SPK: 20125%25.1Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20151%*30.2Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

18 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-05RE

L3650-05RE

SW8082A

08/06/20

08/11/20

CAULKING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

5 08/12/20 11:21 PB130902

CAS Number Parameter Conc. Qualifier

7.33 10000Units:

PCB

g

PO070503.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.35U0.083Aroclor-101612674-11-2 0.083 mg/Kg0.35U0.14Aroclor-122111104-28-2 0.14 mg/Kg0.35U0.093Aroclor-123211141-16-5 0.093 mg/Kg0.35U0.12Aroclor-124253469-21-9 0.12 mg/Kg0.35U0.12Aroclor-124812672-29-6 0.12 mg/Kg0.35U0.13Aroclor-125411097-69-1 0.13 mg/Kg0.35U0.084Aroclor-126237324-23-5 0.084 mg/Kg0.35U0.079Aroclor-126811100-14-4 0.079 mg/Kg0.35U0.058Aroclor-126011096-82-5 0.058

SURROGATES

SPK: 20132%26.4Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20143%*28.6Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

19 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-06

L3650-06

SW8082A

08/06/20

08/11/20

GLAZING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

10 08/12/20 13:55 PB130902

CAS Number Parameter Conc. Qualifier

3.52 10000Units:

PCB

g

PO070512.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg1.40U0.35Aroclor-101612674-11-2 0.35 mg/Kg1.40U0.57Aroclor-122111104-28-2 0.57 mg/Kg1.40U0.39Aroclor-123211141-16-5 0.39 mg/Kg1.40U0.50Aroclor-124253469-21-9 0.50 mg/Kg1.40U0.51Aroclor-124812672-29-6 0.51 mg/Kg1.40U0.56Aroclor-125411097-69-1 0.56 mg/Kg1.40U0.35Aroclor-126237324-23-5 0.35 mg/Kg1.40U0.33Aroclor-126811100-14-4 0.33 mg/Kg1.40U0.24Aroclor-126011096-82-5 0.24

SURROGATES

SPK: 20111%22.1Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 2087%17.4Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between the two GC columns

S = Indicates estimated value where valid five-point calibration was not performed prior to analyte detection in sample.

Q = indicates LCS control criteria did not meet requirements () = Laboratory InHouse Limit

M = MS/MSD acceptance criteria did not meet requirements

Comments:

A

B

C

20 of 47L3650

Project:

Client Sample ID:

Lab Sample ID:

Analytical Method:

Sample Wt/Vol:

Soil Aliquot Vol:

Date Collected:

Date Received:

SDG No.:

Matrix:

% Moisture:

Final Vol:

CHA Companies, Inc.

James J. Peters VA Medical Center

PCB-080620-SR-07

L3650-07

SW8082A

08/06/20

08/11/20

GLAZING

File ID/Qc Batch: Dilution: Date Analyzed Prep Batch ID

10 08/11/20 21:55 PB130902

CAS Number Parameter Conc. Qualifier

5.15 10000Units:

PCB

g

PO070490.D

Test:uL uL

L3650

LOQ / CRQL

Decanted:

PH :

Extraction Type:

GPC Factor : 1.0

Injection Volume :

284 Sheffield Street, Mountainside, NJ 07092 Phone: 908 789 8900 Fax: 908 789 8922

MDL Units

Prep Date

08/11/20 12:30

TARGETS

mg/Kg0.99U0.24Aroclor-101612674-11-2 0.24 mg/Kg0.99U0.39Aroclor-122111104-28-2 0.39 mg/Kg0.99U0.27Aroclor-123211141-16-5 0.27 mg/Kg0.99U0.34Aroclor-124253469-21-9 0.34 mg/Kg0.99U0.35Aroclor-124812672-29-6 0.35 mg/Kg0.99U0.38Aroclor-125411097-69-1 0.38 mg/Kg0.99U0.24Aroclor-126237324-23-5 0.24 mg/Kg0.99U0.22Aroclor-126811100-14-4 0.22 mg/Kg0.99U0.17Aroclor-126011096-82-5 0.17

SURROGATES

SPK: 20228%*45.6Tetrachloro-m-xylene877-09-8 10 - 166

SPK: 20226%*45.3Decachlorobiphenyl2051-24-3 60 - 125

* = Values outside of QC limits

J = Estimated ValueU = Not Detected

B = Analyte Found in Associated Method BlankLOQ = Limit of Quantitation

N = Presumptive Evidence of a CompoundMDL = Method Detection Limit

E = Value Exceeds Calibration Range D = Dilution

LOD = Limit of Detection

P = Indicates >25% difference for detected concentrations between…